20:41 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest PRMT5 inhibitors could help treat glioblastoma multiforme (GBM). In human GBM cell lines, shRNA targeting PRMT5 or the PRMT5 inhibitor EPZ015666 decreased proliferation compared with no...
21:55 , Oct 4, 2017 |  BC Extra  |  Preclinical News

Team ties target to GBM progression, identifies biomarker

In a paper published in Cancer Cell , researchers at Massachusetts Institute of Technology and Harvard Medical School used an in vivo short hairpin RNA screen to identify an epigenetic regulator, protein arginine methyltransferase 5...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies identified an inhibitor of PRMT5 histone methyltransferase activity that could help treat CML. In patient CD34 + hematopoietic stem cells from peripheral blood...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methionine adenosyltransferase 2A (MAT2A); protein arginine methyltransferase 5 (PRMT5); RIO kinase 1 (RIOK1); methylthioadenosine phosphorylase (

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting the MAT2A / PRMT5 / RIOK1 axis could help treat MTAP-deficient colon cancer. In a human MTAP-deficient colon cancer cell line, shRNA targeting MAT2A,...
07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein arginine methyltransferase 5 (PRMT5)

Cancer INDICATION: Mantle cell lymphoma (MCL) Cell culture and mouse studies suggest a PRMT5 inhibitor could help treat MCL. Screening of a diverse library of small molecules in multiple cellular assays identified a lead compound...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

Epizyme, GlaxoSmithKline preclinical data

In mouse xenograft models of MCL, twice-daily doses of 25, 50, 100 and 200 mg/kg EPZ015666 for 21 days each significantly reduced tumor volume vs. vehicle-treated controls (p<0.0001 for all). Data were presented at the...
08:00 , Jan 15, 2015 |  BC Innovations  |  Product R&D

Epizyme's mantle piece

Epigenetic modulation notched another target last month when Epizyme Inc. announced a preclinical compound against PRMT5 - an arginine methyltransferase - that shows activity in mouse models of mantle cell lymphoma. The next step is...